alvocidib and baicalein

alvocidib has been researched along with baicalein* in 1 studies

Other Studies

1 other study(ies) available for alvocidib and baicalein

ArticleYear
Design, synthesis, and primary activity assays of baicalein derivatives as cyclin-dependent kinase 1 inhibitors.
    Chemical biology & drug design, 2021, Volume: 98, Issue:4

    Malignant tumor is a disease with high mortality. Traditional treatment methods have many disadvantages, such as side-effects, drug resistance. Because cyclin-dependent kinase 1 (CDK1) plays an indispensable role in cell cycle regulation, it became an attractive target in rational anti-cancer drug discovery. Herein, we reported a series of baicalein derivatives, which remarkably repressed the proliferation of MCF-7 tumor cells and the activity of CDK1/cyclin B kinase. Among them, compound 4a displayed better inhibition rate than flavopiridol against MCF-7 proliferation at the concentration of 50 μg/ml, comparable to compound CGP74514A, while compound 3o possessed the best activity against CDK1/cyclin B kinase (IC

    Topics: Antineoplastic Agents; Apoptosis; CDC2 Protein Kinase; Cell Proliferation; Cyclin B; Drug Screening Assays, Antitumor; Flavanones; Flavonoids; Humans; MCF-7 Cells; Molecular Docking Simulation; Piperidines; Protein Binding; Protein Kinase Inhibitors; Structure-Activity Relationship

2021